See more : Vicinity Centres (VCX.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Electromed, Inc. (ELMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Electromed, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Mineral Mountain Resources Ltd. (MNRLF) Income Statement Analysis – Financial Results
- Chaoda Modern Agriculture (Holdings) Limited (0682.HK) Income Statement Analysis – Financial Results
- Interlink Communication Public Company Limited (ILINK.BK) Income Statement Analysis – Financial Results
- Light Science Technologies Holdings Plc (LST.L) Income Statement Analysis – Financial Results
- Arteris, Inc. (AIP) Income Statement Analysis – Financial Results
Electromed, Inc. (ELMD)
About Electromed, Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.72M | 48.07M | 41.66M | 35.76M | 32.47M | 31.30M | 28.70M | 25.86M | 22.99M | 19.41M | 15.49M | 15.10M | 19.52M | 19.00M | 14.30M | 13.00M | 8.75M |
| Cost of Revenue | 12.99M | 11.55M | 10.22M | 8.45M | 7.27M | 7.45M | 5.84M | 5.29M | 5.12M | 5.81M | 4.85M | 4.66M | 5.38M | 5.23M | 3.71M | 3.34M | 2.15M |
| Gross Profit | 41.73M | 36.52M | 31.44M | 27.31M | 25.20M | 23.85M | 22.86M | 20.57M | 17.88M | 13.60M | 10.63M | 10.45M | 14.15M | 13.78M | 10.60M | 9.66M | 6.61M |
| Gross Profit Ratio | 76.26% | 75.98% | 75.47% | 76.36% | 77.61% | 76.19% | 79.64% | 79.53% | 77.75% | 70.07% | 68.66% | 69.18% | 72.45% | 72.50% | 74.08% | 74.30% | 75.47% |
| Research & Development | 656.00K | 916.00K | 1.36M | 1.72M | 1.05M | 583.31K | 251.44K | 596.88K | 380.39K | 315.65K | 466.06K | 603.38K | 920.77K | 1.03M | 600.99K | 357.87K | 271.24K |
| General & Administrative | 33.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.60M | 16.40M | 14.39M | 11.97M | 10.91M | 11.67M | 12.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 499.00K | 589.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.49M | 31.60M | 27.11M | 22.44M | 19.94M | 20.45M | 19.60M | 16.40M | 14.39M | 11.97M | 10.91M | 11.67M | 12.62M | 10.87M | 8.20M | 6.85M | 6.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -12.00K | -913.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.87M | 8.20M | 6.85M | 6.00M |
| Operating Expenses | 35.15M | 32.51M | 28.47M | 24.17M | 20.08M | 21.03M | 19.85M | 17.00M | 14.77M | 12.29M | 11.37M | 12.28M | 13.54M | 11.91M | 8.80M | 7.20M | 6.27M |
| Cost & Expenses | 48.14M | 44.06M | 38.69M | 32.62M | 27.35M | 28.48M | 25.69M | 22.29M | 19.88M | 18.10M | 16.23M | 16.93M | 18.92M | 17.13M | 12.51M | 10.54M | 8.42M |
| Interest Income | 455.00K | 78.00K | 25.00K | 39.00K | 120.75K | 90.71K | 0.00 | 17.04K | 0.00 | 284.00 | 12.39K | 16.72K | 8.40K | 10.92K | 6.42K | 8.75K | 24.82K |
| Interest Expense | 0.00 | 0.00 | 25.00K | 0.00 | 0.00 | 0.00 | 19.87M | 66.91K | 66.81K | 85.99K | 91.40K | 133.56K | 177.13K | 191.33K | 269.85K | 279.19K | 501.69K |
| Depreciation & Amortization | 841.00K | 613.00K | 628.00K | 610.00K | 738.23K | 925.23K | 790.03K | 755.13K | 738.70K | 736.22K | 695.55K | 589.86K | 532.63K | 449.47K | 351.75K | 318.95K | 268.40K |
| EBITDA | 7.42M | 4.62M | 3.60M | 3.75M | 5.86M | 3.74M | 3.80M | 4.32M | 3.85M | 2.05M | -32.65K | -1.24M | 1.15M | 2.33M | 2.15M | 2.77M | 627.43K |
| EBITDA Ratio | 13.56% | 9.61% | 8.64% | 10.49% | 18.04% | 11.96% | 13.24% | 16.72% | 16.74% | 10.54% | -0.21% | -8.08% | 5.88% | 12.21% | 15.06% | 21.41% | 7.17% |
| Operating Income | 6.58M | 4.01M | 2.97M | 3.14M | 5.12M | 2.82M | 3.01M | 3.57M | 3.11M | 1.31M | -740.59K | -1.83M | 606.34K | 1.87M | 1.80M | 2.46M | 334.22K |
| Operating Income Ratio | 12.03% | 8.34% | 7.13% | 8.78% | 15.76% | 9.00% | 10.48% | 13.80% | 13.52% | 6.75% | -4.78% | -12.10% | 3.11% | 9.84% | 12.56% | 18.89% | 3.82% |
| Total Other Income/Expenses | 455.00K | 78.00K | 25.00K | 27.00K | 120.75K | 101.82K | -276.35K | -49.87K | -66.81K | -85.71K | -79.00K | -116.88K | -168.73K | -191.33K | -263.43K | -270.45K | -476.87K |
| Income Before Tax | 7.04M | 4.09M | 3.00M | 3.17M | 5.24M | 2.91M | 3.03M | 3.52M | 3.04M | 1.22M | -819.59K | -1.94M | 437.61K | 1.68M | 1.53M | 2.19M | -142.65K |
| Income Before Tax Ratio | 12.86% | 8.50% | 7.19% | 8.86% | 16.14% | 9.29% | 10.55% | 13.61% | 13.23% | 6.31% | -5.29% | -12.87% | 2.24% | 8.83% | 10.71% | 16.81% | -1.63% |
| Income Tax Expense | 1.89M | 920.00K | 692.00K | 805.00K | 1.08M | 940.00K | 1.13M | 1.29M | 830.00K | 132.00K | 469.00K | -615.00K | 251.00K | 623.00K | 599.00K | 830.00K | -427.00K |
| Net Income | 5.15M | 3.17M | 2.31M | 2.36M | 4.16M | 1.97M | 1.90M | 2.23M | 2.21M | 1.09M | -1.29M | -1.33M | 186.61K | 1.06M | 916.34K | 1.33M | 267.85K |
| Net Income Ratio | 9.41% | 6.59% | 5.53% | 6.61% | 12.81% | 6.29% | 6.63% | 8.62% | 9.62% | 5.63% | -8.32% | -8.80% | 0.96% | 5.55% | 6.41% | 10.25% | 3.06% |
| EPS | 0.60 | 0.37 | 0.27 | 0.28 | 0.50 | 0.24 | 0.23 | 0.27 | 0.27 | 0.13 | -0.16 | -0.16 | 0.02 | 0.14 | 0.15 | 0.22 | 0.05 |
| EPS Diluted | 0.58 | 0.36 | 0.26 | 0.27 | 0.47 | 0.23 | 0.22 | 0.26 | 0.27 | 0.13 | -0.16 | -0.16 | 0.02 | 0.13 | 0.15 | 0.22 | 0.04 |
| Weighted Avg Shares Out | 8.56M | 8.46M | 8.47M | 8.57M | 8.40M | 8.31M | 8.21M | 8.17M | 8.14M | 8.12M | 8.05M | 8.11M | 8.11M | 7.82M | 6.08M | 5.99M | 5.44M |
| Weighted Avg Shares Out (Dil) | 8.86M | 8.70M | 8.77M | 8.91M | 8.83M | 8.63M | 8.62M | 8.46M | 8.25M | 8.15M | 8.11M | 8.11M | 8.11M | 7.84M | 6.11M | 6.02M | 6.45M |
Electromed, Inc. (ELMD) Q4 Earnings Meet Estimates
Electromed, Inc. (ELMD) delivered earnings and revenue surprises of 0.00% and 1.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Electromed, Inc. Announces Fiscal 2021 Fourth Quarter and Full Year Financial Results
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months (“Q4 FY 2021”) and full year (“FY 2021”) ended June 30, 2021. Q4...
Electromed, Inc. (ELMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Electromed, Inc. (ELMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Electromed, Inc. Schedules its Fourth Quarter Fiscal 2021 Financial Results Conference Call for August 24, 2021 at 5:00 p.m. ET
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2021 fourth quarter ended June 30, 2021,...
Electromed, Inc. Schedules its Fourth Quarter Fiscal 2021 Financial Results Conference Call for August 24, 2021 at 5:00 p.m. ET
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2021 fourth quarter ended June 30, 2021,...
Electromed, Inc. Announces Select Preliminary Unaudited Financial Results for Fourth Quarter Fiscal 2021
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced select preliminary unaudited financial results for the three months ended June 30, 2021 (“Q4 FY 2021”). For Q4 FY...
New Strong Sell Stocks for June 3rd
ADSK, BNR, NET, ELMD, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on June 3, 2021
Electromed, Inc. Announces Authorization of $3.0 Million Stock Repurchase Program
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that its Board of Directors has approved a $3.0 million stock repurchase authorization, effective as of May 26, 2021....
Electromed, Inc. Named 2021 Quality Plant of the Year
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (NYSE American: ELMD) was named Quality Magazine's 2021 Plant of the Year. Electromed was selected for the honor from the 2021 Quality Leadership Top 100 Company survey published annually by the magazine. The metrics measure...
New Strong Sell Stocks for May 13th
PRTS, CIGI, ELMD, LLY, and TTWO have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2021
Source: https://incomestatements.info
Category: Stock Reports